Jascayd generics — when can they launch?
Jascayd (NERANDOMILAST) · Boehringer Ingelheim · 10 active US patents · 0 expired
Where Jascayd sits in the generic timeline
Mid-term cliff: earliest active US patent for Jascayd expires in 2029 (~4 years). Generic developers typically begin ANDA bioequivalence studies 3-4 years ahead of this date. Paragraph IV filings + Hatch-Waxman 30-month stays may shift the effective entry by another 18-36 months.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 8 patents
- Composition of Matter — 2 patents
FDA U-codes carved out by Jascayd patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-4298 | (no description) |
U-4372 | (no description) |
U-4373 | (no description) |
Sample patent estate
Showing 6 of 10 active US patents. View full estate on the Jascayd drug page →
-
This patent protects a class of compounds, specifically piperidinodihydrothienopyrimidines, for use in treating various diseases and complaints.USPTO title: Substituted piperazino-dihydrothienopyrimidines
-
This patent protects a class of compounds, specifically piperidinodihydrothienopyrimidines, for use in treating various diseases and complaints.USPTO title: Substituted piperazino-dihydrothienopyrimidines
-
This patent protects novel piperidino-dihydrothienopyrimidine sulfoxides and their derivatives for use in treating COPD and asthma.USPTO title: Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
-
This patent protects novel piperidino-dihydrothienopyrimidine sulfoxides and their derivatives for use in treating COPD and asthma.USPTO title: Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
-
This patent protects piperidino-dihydrothienopyrimidine sulfoxides and their use for treating respiratory tract diseases such as COPD and asthma.USPTO title: Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
-
This patent protects piperidino-dihydrothienopyrimidine sulfoxides and their use for treating respiratory tract diseases such as COPD and asthma.USPTO title: Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
Sources
- FDA Orange Book — patents listed against Jascayd (NDA filed 2025)
- Jascayd drug profile — full patent estate, indications, clinical trials, pricing
- Boehringer Ingelheim patent portfolio
- Patent cliff 2029 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Jascayd — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →